CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade ORIC Pharmaceuticals, Inc. - ORIC CFD

9.11
5.2%
Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024929 %
Charges from full value of position ($-0.25)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.024929%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002707 %
Charges from full value of position ($0.03)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.002707%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 9.61
Open 9.56
1-Year Change 71.63%
Day's Range 9.05 - 9.56
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 16, 2024 9.61 0.43 4.68% 9.18 9.71 9.18
Oct 15, 2024 9.47 0.29 3.16% 9.18 9.57 9.18
Oct 14, 2024 9.50 0.34 3.71% 9.16 9.77 9.13
Oct 11, 2024 9.29 0.06 0.65% 9.23 9.35 9.10
Oct 10, 2024 9.24 0.14 1.54% 9.10 9.36 8.94
Oct 9, 2024 9.24 -0.07 -0.75% 9.31 9.46 9.09
Oct 8, 2024 9.45 -0.05 -0.53% 9.50 9.82 9.41
Oct 7, 2024 9.47 -0.06 -0.63% 9.53 9.60 9.37
Oct 4, 2024 9.57 0.03 0.31% 9.54 9.73 9.39
Oct 3, 2024 9.52 0.00 0.00% 9.52 9.70 9.42
Oct 2, 2024 9.74 0.18 1.88% 9.56 9.84 9.51
Oct 1, 2024 10.02 -0.11 -1.09% 10.13 10.13 9.64
Sep 30, 2024 10.21 -0.19 -1.83% 10.40 10.85 9.96
Sep 27, 2024 10.61 0.28 2.71% 10.33 10.81 10.33
Sep 26, 2024 10.32 0.24 2.38% 10.08 10.49 9.90
Sep 25, 2024 9.97 -0.71 -6.65% 10.68 10.98 9.60
Sep 24, 2024 10.71 -0.06 -0.56% 10.77 10.80 10.49
Sep 23, 2024 10.71 -0.57 -5.05% 11.28 11.43 10.62
Sep 20, 2024 11.24 0.27 2.46% 10.97 11.66 10.74
Sep 19, 2024 11.13 0.26 2.39% 10.87 12.76 10.87

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

ORIC Pharmaceuticals, Inc. Company profile

About ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its product candidates include ORIC-101, ORIC-533, ORIC-944 and ORIC-114. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its ORIC-944, is being developed for prostate cancer and breast cancer.

Financial summary

BRIEF: For the nine months ended 30 September 2021, ORIC Pharmaceuticals Inc revenues was not reported. Net loss increased 23% to $55.9M. Higher net loss reflects Research and development - Balancing val increase from $15.4M to $36.5M (expense), General and administrative - Balancing increase of 93% to $10.2M (expense), Stock-based Compensation in SGA increase from $1.9M to $5.8M (expense).

Industry: Bio Therapeutic Drugs

240 E. Grand Ave
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

News

US earnings seasons off to a solid start as focus shifts to tech giants

The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.

14:31, 17 October 2024

ECB Preview: cooling growth and inflation call for another rate cut

Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.

12:41, 16 October 2024

Australian labour force data forecast to reveal stable jobs market

Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.

07:41, 15 October 2024

Applying fundamental and technical strategies to Gold Trading

Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.

08:00, 14 October 2024

S&P 500 expected to deliver modest earnings growth in Q3

Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.

12:40, 11 October 2024

US Core CPI tipped to remain unchanged in September

US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.

07:10, 9 October 2024

RBNZ expected to deliver “jumbo” rate cut

The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.

08:48, 8 October 2024

People also watch

Oil - Crude

70.50 Price
+0.330% 1D Chg, %
Long position overnight fee 0.0133%
Short position overnight fee -0.0352%
Overnight fee time 21:00 (UTC)
Spread 0.040

BTC/USD

67,930.45 Price
+0.320% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,709.55 Price
+1.270% 1D Chg, %
Long position overnight fee -0.0177%
Short position overnight fee 0.0095%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

20,213.30 Price
+0.290% 1D Chg, %
Long position overnight fee -0.0249%
Short position overnight fee 0.0027%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading